ZIVO Bioscience (ZIVO) Expected to Announce Quarterly Earnings on Wednesday

ZIVO Bioscience (NASDAQ:ZIVO) will likely be posting its results before the market opens on Wednesday, February 25th. Analysts expect ZIVO Bioscience to post earnings of ($0.29) per share and revenue of $0.0940 million for the quarter.

ZIVO Bioscience Price Performance

NASDAQ ZIVO opened at $10.00 on Monday. ZIVO Bioscience has a 1 year low of $6.95 and a 1 year high of $21.00. The stock has a market capitalization of $40 million, a PE ratio of -2.05 and a beta of 0.19. The business’s 50-day moving average is $9.27 and its 200 day moving average is $12.03.

ZIVO Bioscience Company Profile

ZIVO Bioscience is a clinical-stage biotechnology company focused on developing precision live biotherapeutics to prevent and treat gastrointestinal infections in both animal and human health markets. The company applies synthetic biology, microbiology and fermentation technologies to engineer proprietary bacterial strains that produce targeted lactic acid and antimicrobial compounds. Its pipeline includes ZB-01, an orally administered therapy for recurrent Clostridioides difficile infections in humans, and ZB-02, a feed-additive candidate aimed at reducing Salmonella colonization in poultry.

Founded in 2016 and headquartered in Carlsbad, California, ZIVO Bioscience leverages exclusive licensing agreements with academic institutions to advance its lead programs through preclinical and early clinical development.